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OBJECTIVE To determine the effect of pulmonary blood flow (Qp) on nitric oxide (NO) production in
patients with increased Qp due to an atrial septal defect (ASD).
BACKGROUND Alterations in pulmonary vascular NO production have been implicated in the development
of pulmonary hypertension secondary to increased Qp. In vitro, acute changes in flow or shear
stress alter NO production. However, the effect of Qp on lung NO production in vivo is
unclear.
METHODS Nineteen patients (2.4–61 years of age, median 17) with secundum ASD undergoing device
closure were studied. Before, and 30 min after ASD closure, exhaled NO and plasma nitrate
concentration were measured by chemiluminescence (NOA 280, Sievers, Boulder, Colorado).
RESULTS Before ASD closure, all patients had increased Qp (Qp: systemic blood flow [Qs] of 2.0 6
0.7) and normal mean pulmonary arterial pressure (13.4 6 3.1 mm Hg). Atrial septal defect
device closure decreased Qp from 6.0 6 2.5 to 3.6 6 1.3 L/min/m2 (p , 0.05). Mean
pulmonary arterial pressure was unchanged. Associated with the decrease in Qp, both exhaled
NO (222.1%, p , 0.05) and plasma nitrate concentrations (217.9%, p , 0.05) decreased.
CONCLUSIONS These data represent the first demonstration that acute changes in Qp alter pulmonary NO
production in vivo in humans. Exhaled NO determinations may provide a noninvasive
assessment of pulmonary vascular NO production in patients with congenital heart disease.
Potential correlations between exhaled NO, pulmonary vascular reactivity and pulmonary
hypertension warrant further study. (J Am Coll Cardiol 2000;35:463–7) © 2000 by the
American College of Cardiology
Nitric oxide (NO) is an endothelium-derived relaxing factor
synthesized by the vascular endothelium from the oxidation
of the guanidino nitrogen moiety of L-arginine (1). After
certain stimuli, such as the receptor binding of specific
vasodilators, NO is synthesized after activation of endothe-
lial NO synthase (eNOS) (2,3). Once released from endo-
thelial cells, NO diffuses into vascular smooth muscle cells,
where it activates soluble guanylate cyclase, the enzyme that
catalyzes the production of guanisone 39,59-cyclic mono-
phosphate (cGMP) from guanosine 39,59-triphosphate.
This results in increased smooth muscle cell concentrations
of cGMP, thus initiating a cascade that results in smooth
muscle relaxation (4). Recent evidence suggests that basal
production of NO is an important mediator of pulmonary
vascular tone, a modulator of pulmonary vascular reactivity
and an inhibitor of platelet aggregation and smooth muscle
mitogenesis (5–8). In addition, aberrations in NO activity
have been demonstrated in patients with congenital heart
disease and increased pulmonary blood flow (Qp), implicat-
ing a role for NO in the pathophysiology of pulmonary
hypertension (9,10).
In vitro data suggest that acute changes in flow or shear
stress regulate the production of endothelial NO production
(11–13). However, the mechanisms by which NO produc-
tion is regulated in vivo are unclear. The purpose of this
study was to determine if acute changes in Qp alter
endogenous NO production in patients with increased Qp
due to congenital heart defects. To this end, we studied
patients with increased Qp due to secundum atrial septal
defects (ASDs) who were undergoing device closure of
ASD in the cardiac catheterization laboratory. This exper-
imental model provides a unique condition in which Qp is
acutely changed without the effects of cardiopulmonary
bypass. To determine changes in endogenous NO produc-
tion, we measured both exhaled NO (an indirect determi-
nant of pulmonary NO production) and plasma nitrate (an
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indirect determinant of whole body NO production) con-
centrations before and 30 minutes after ASD closure
(14,15).
METHODS
Patient selection. Children and adults with secundum
ASDs were enrolled in the study. All patients were concur-
rently enrolled in a multicentered trial evaluating ASD
closure with the CardioSEAL (Nitinol Medical Technolo-
gies, Boston, Massachusetts) device (16). Patients were
excluded from the study if they had a history of reactive
airway disease, renal insufficiency or were taking anti-
inflammatory medication.
Experimental protocol. All patients were fasted for 12 h
before the procedure. Patients were then brought to the
cardiac catheterization laboratory where they were sedated,
intubated and mechanically ventilated with an FiO2 of
0.25. Normocarbic ventilation was maintained utilizing an
Ohmeda Modulus 2 plus (Ohmeda Inc., Austell, Georgia).
Throughout the procedure, FiO2, minute ventilation and
ventilator flow were held constant. General anesthesia was
maintained with intravenous or inhalational agents. Base-
line (preclosure) measurements of pulmonary and systemic
arterial pressures and heart rate were obtained (hemody-
namic variables). Pulmonary and systemic arterial and ve-
nous blood samples were obtained for measurement of
hemoglobin and hemoglobin oxygen saturation. Oxygen
consumption was estimated based on heart rate and body
surface area, and Qp and systemic blood flow (Qs) were
estimated by the Fick equation. Before implantation of the
device, after a minimum of 30 min of stable mechanical
ventilation, breath-to-breath determinations of exhaled NO
were obtained for 30 s. In addition, femoral venous blood
was obtained for plasma nitrate (NOx) determinations.
Thirty minutes after ASD device closure, repeat measure-
ments of the hemodynamic variables, hemoglobin and
hemoglobin oxygen saturation, Qp, Qs, exhaled NO and
plasma NOx were obtained. Each patient had exhaled NO
determinations at least two times before the preclosure value
was obtained to insure a steady-state value. To determine if
cardiac catheterization alone, without changes in blood
flows, altered plasma NOx concentrations, plasma was
obtained in six additional patients undergoing diagnostic
catheterization. Samples were obtained before and 30 min
after angiography in these patients. Exhaled NO was not
determined in these patients because their trachea were not
intubated.
The protocol was approved by the Committee on Human
Research, University of California, San Francisco. Written,
informed consent was obtained from all patients or their
parents before cardiac catheterization.
Measurements. Pulmonary arterial pressure was measured
using a side-hole balloon catheter (Arrow Intl., Reading,
Pennsylvania) connected via a fluid-filled system to a pres-
sure transducer (Abbott Labs, North Chicago, Illinois).
Mean pressure was obtained by electrical integration. Sys-
temic arterial pressure was measured by an automated
sphygmomanometer (Critikon Inc., Tampa, Florida) placed
on the left arm. Heart rate was measured with a cardiota-
chometer. Systemic arterial blood gases and pH were
measured using a 850 pH/Blood Gas Analyzer (Ciba-
Corning Diagnostic, Tarrytown, New York). Hemoglobin
and hemoglobin oxygen saturations were measured in whole
blood using an OSM2 oximeter (Radiometer America Inc.,
Westlake, Ohio). Oxygen consumption was assumed based
on heart rate and body surface area (17). Pulmonary and
systemic blood flows were estimated by the Fick equation.
Exhaled NO determinations. Expiratory gas was sampled
continuously form a side port attached to the ventilator
circuit at a rate of 200 ml/min. Exhaled NO was measured
using a chemiluminescence analyzer (NOA 280, Sievers,
Boulder, Colorado) as previously described (18). The analog
signal was digitalized and stored continuously on a com-
puter using data acquisition software (Sievers). Utilizing an
inline pressure transducer to determine the beginning and
end of exhalation, NO was determined on a breath-by-
breath basis. The average concentration of NO at end-
expiration over a 30 s time period was used as the exhaled
NO concentration. The preclosure values were taken im-
mediately before delivery of the device, and the postclosure
values were taken 30 minutes after device closure. Calibra-
tion was performed daily. Previous investigations have
demonstrated linearity of the analyzer over the concentra-
tions measured (18).
NOx determinations. Blood samples (1 to 2 ml) were
collected in iced vacutainer tubes. The samples were centri-
fuged (4000 g 3 15 min) and the resulting plasma stored in
polypropylene storage tubes at 270°C. Before analysis,
plasma samples were deproteinized with 0.2M HCl. In
solution, NO reacts with molecular oxygen to form nitrite
and with oxyhemoglobin and superoxide anion to form
NOx. The nitrite and NOx were reduced using vanadium
(III) and hydrochloric acid at 90°C. Nitric oxide was then
purged from solution resulting in a peak of NO. Therefore,
this value represents total NO, nitrite and NOx. This peak
was then detected by chemiluminescence (NOA 280,
Abbreviations and Acronyms
ASD 5 atrial septal defect
cGMP 5 guanisone 39,59-cyclic monophosphate
eNOS 5 endothelial NO synthase
NO 5 nitric oxide
NOx 5 nitrate
Qp 5 pulmonary blood flow
Qs 5 systemic blood flow
SD 5 standard deviation
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Sievers). The detection limit is 1 nM/ml of NOx. Calibra-
tion was performed daily.
Data analysis. The mean 6 standard deviation (SD) were
calculated for the hemodynamic variables, Qp, Qs, exhaled
NO and plasma NOx concentrations. The hemodynamic
variables, Qp, Qs and exhaled NO concentrations were
compared before and after ASD closure by the paired t test.
Plasma NOx concentrations were not normally distributed.
Therefore, they were compared before and after ASD
closure by the Wilcoxon signed-rank test. A p , 0.05 was
considered significant.
RESULTS
Twenty-six patients were enrolled in the study. During
cardiac catheterization, seven patients were excluded from
the CardioSEAL ASD device closure protocol: five due to
large ASD size (.20 mm) and two due to the presence of
associated defects. Nineteen patients (age 2.4 to 61 years,
median 12 years, 11 female and 8 male) completed the
study; no additional patients were excluded. Two patients
did not have exhaled NO determinations because of tech-
nical problems. These patients had plasma NOx determina-
tions only. Two other patients did not have plasma NOx
determinations because of error in sample handling. These
patients had exhaled NO determinations only. All enrolled
patients had both pre- and post-value determinations.
The median ASD size was 11.0 mm, with a range of 7 to
18 mm. Before ASD closure, all patients had increased Qp
(Qp:Qs 5 2.0 6 0.7) and normal mean pulmonary arterial
pressures (Table 1). Exhaled NO concentrations were un-
changed over the 30 min period before ASD closure
(7.89 6 7.4 vs. 7.90 6 7.2 ppb, n 5 15).
Atrial septal defect device closure decreased Qp (Table 1,
p , 0.05). Mean pulmonary and systemic arterial pressures
were unchanged. Associated with this decrease in Qp, there
was a significant decrease in both exhaled NO (from 7.6 6
7.1 SD to 5.4 6 6.9 ppb, p , 0.05) and plasma NOx
concentrations (from 43.4 6 29.3 to 35.3 6 26.6 mM, p ,
0.05) (Figs. 1 and 2). Systemic arterial blood gases and pH
and hemoglobin were unchanged.
Plasma NOx concentrations did not change in the six
patients who underwent diagnostic catheterization without
changes in blood flows (from 19.8 6 11.3 to 21.0 6
11.1 mM).
DISCUSSION
In vitro data suggest that acute changes in flow or shear
stress regulate NOS activity. For example, in cultured
endothelial cells, increases in flow produce an increase in
NO production and eNOS gene expression (11–13,19).
However, the acute effect of Qp on NO production in vivo
in humans was unknown. This study represents the first
demonstration that decreases in Qp decrease endogenous
NO production in humans. To demonstrate the effects of
Qp on NO production, we utilized a unique study design:
we measured changes in exhaled NO and plasma NOx in
patients undergoing nonsurgical ASD device closure in the
cardiac catheterization laboratory. The majority of surgical
procedures that change Qp utilize cardiopulmonary bypass.
However, cardiopulmonary bypass changes pulmonary NO
production independent of changes in Qp; it produces
inflammatory lung injury and pulmonary vascular endothe-
lial cell injury (20). During ASD device closure, patients
Table 1. Hemodynamic Measurements Pre- and Post-ASD
Device Closure
Preclosure Postclosure
Qp (L/min/m2) 6.20 6 2.1 3.84 6 1.2*
Qs (L/min/m2) 3.12 6 0.8 3.40 6 1.1
Qp:Qs 2.04 6 0.7 1.13 6 0.2*
Mean PAP (mm Hg) 13.4 6 3.1 14.5 6 5.7
Mean SAP (mm Hg) 68.4 6 9.1 70.8 6 9.5
RAP (mm Hg) 4.7 6 1.9 5.0 6 3.1
HR (beats/min) 85 6 23 74 6 15
SaO2 99 6 1 99 6 1
Data expressed as mean 6 SD. N 5 19 patients. *p , 0.05 vs. preclosure.
ASD 5 atrial septal defect; HR 5 heart rate; PAP 5 pulmonary arterial pressure;
Qp 5 pulmonary blood flow; Qs 5 systemic blood flow; Qp:Qs 5 pulmonary to
systemic blood flow ratio; RAP 5 right atrial pressure; SaO2 5 systemic oxygen
saturation; SAP 5 systemic arterial pressure.
Figure 1. Exhaled NO concentrations (ppb) decreased after ASD
device closure. Values are mean 6 S.E., N 5 17. p , 0.05 vs.
preclosure (paired t-test). ASD 5 atrial septal defect.
Figure 2. Plasma NOx concentrations (mM) decreased after ASD
device closure. Values are mean 6 S.E., N 5 17. p , 0.05 vs.
preclosure (Wilcoxon signed-rank test). ASD 5 atrial septal
defect.
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undergo a significant decrease in Qp (;50%) without
cardiopulmonary bypass, making this an excellent model to
assess the effect of Qp on NO production.
This unique study design also minimized the limitations
of in vivo determinations of endogenous NO production.
To determine changes in endogenous NO production, we
measured changes in exhaled NO and plasma NOx. Exhaled
NO is an indirect determination of pulmonary NO produc-
tion (14). The major sources of exhaled NO are the
nasopharynx, sinuses and respiratory tract (21). In this
study, all patients were intubated for the procedure. Sam-
pling in intubated patients excludes the nasopharynx and
sinuses, isolating the source to the respiratory tract. Within
the respiratory tract, all three isoforms of NOS have been
found (22,23). The major constitutive isoform in the lung is
eNOS, which is found predominantly in pulmonary vascular
endothelial cells, with small amounts found in the bronchial
epithelium. Small amounts of the other constitutive iso-
form, neuronal NOS, have been found in the nonadrener-
gic, noncholinergic nerves of the lung. The inducible
isoform, iNOS, is found in the airway epithelium, inflam-
matory cells and alveolar pneumocytes. Cell culture studies
suggest that several hours are required for the inducible
NOS to produce NO following a stimuli (24). In this study,
we determined changes within 30 min, suggesting that these
changes are reflective of changes in constitutive NO pro-
duction, the majority being eNOS-derived NO production.
In addition to endogenous NO production, exhaled NO
determinations may be altered by changes in minute venti-
lation, expiratory flow rate and inspired oxygen concentra-
tions (25,26). However, during the study period all of these
variables were held constant, isolating any change in exhaled
NO to changes in endogenous production.
Plasma NOx is an indirect determination of total body
NO production (15). Endogenous NO may be found in
plasma as dissolved NO gas, nitrite anions and the majority
as NOx anions (27). Utilizing vanadium and HCL reduc-
tion, both nitrite and nitrate are reduced to NO, which is
then determined by chemiluminescence. Therefore, we
determined all potential sources of endogenous NO produc-
tion. We found a 17.9% decrease in plasma NOx concen-
trations associated with a 40% decrease in Qp. Since plasma
NOx concentrations represent total body endogenous NO
production, we were surprised by the magnitude of change
demonstrated in the plasma concentrations in this study. In
fact, since the half-life of plasma nitrate is 3.8 h, the changes
demonstrated after 30 min may underestimate the total
decrease (15). However, human and animal data suggest
that endogenous pulmonary NO production is increased in
subjects with increased Qp (28,29). Therefore, pulmonary
NO production may be a significant proportion of total
body NO production in this setting. In fact, one study
demonstrated a similar 23% decrease in plasma NOx in
children following surgical closure of ventricular septal
defects (28). In addition to endogenous NO production,
plasma NOx concentrations are effected by diet, changes in
renal function and changes in extracellular volume (15).
During our study period, all patients were fasted for 12 h
and had stable renal function, isolating any change in
plasma NOx to changes in endogenous production (30).
In addition to the indirect measurements of endogenous
NO production, one additional limitation of this study was
noteworthy. Because the only patients intubated and me-
chanically ventilated during cardiac catheterization are those
undergoing ASD device closure, identical control patients,
who were undergoing catheterization without changes in
blood flow, were not available. Therefore, we determined
exhaled NO at least two times before obtaining preclosure
values to insure that the values had reached a steady state. In
addition, to determine if catheterization with angiography
alone changed NO production, we measured NOx concen-
trations in six additional patients undergoing catheterization
without changes in blood flow. We found that cardiac
catheterization alone did not change plasma NOx. Exhaled
NO determinations were not made in these patients because
they were spontaneously breathing.
In summary, this study is the first demonstration that
changes in Qp mediate endogenous NO production in vivo
in humans. We utilized a unique study population, patients
undergoing device closure of ASD. This provided a study
design which not only allowed the investigation of acute
changes in Qp without the use of cardiopulmonary bypass,
but also maximized the utility of both in vivo determina-
tions of endogenous NO production. A limitation of the
study was that the exact source NO production could not be
determined by these noninvasive measurements. However,
since the changes measured in this study occurred over a
30 min period, they most likely represent changes in the
constitutive isoforms, the majority being changes in eNOS-
derived pulmonary vascular NO production. It should also
be noted that a reduction in the perfused surface area
secondary to derecruitment of vessels, and not a reduction in
the NO production of individual endothelial cells, cannot be
excluded in this in vivo study design. Alterations in endog-
enous endothelial NO production have been implicated in
the pathophysiology of pulmonary hypertension associated
with increased Qp (6,9). Whether exhaled NO and plasma
NOx will provide clinically useful measures of NO produc-
tion, and thereby be predictive of the progression of pul-
monary hypertension and vascular reactivity, is unknown
and warrants further study.
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